Apixaban-associated Cutaneous Adverse Events: A Synthesis of Case Reports and Pharmacovigilance Signals From a Curated Dataset

Direct oral anticoagulants (DOACs) are integral to modern thromboembolic care, yet dermatologic adverse events attributed to apixaban remain incompletely characterized. We conducted a structured synthesis of published reports and pharmacovigilance analyses describing cutaneous apixaban reactions, with emphasis on clinical presentation, histopathology, management strategies, and outcomes. Six studies were included (four single-patient case reports, one pharmacovigilance analysis, and one comparator case involving low-molecular-weight heparin). Median time to onset was seven days, and resolution occurred at a median of twenty-four days. Lesions presented as purpura, bullae, or necrosis; histology demonstrated leukocytoclastic vasculitis where biopsied. Management universally included apixaban discontinuation, with adjunctive corticosteroids in most cases. Apixaban-associated cutaneous reactions appear rare but typically manifest within one to two weeks of initiation. Early recognition and prompt drug withdrawal are critical to balancing dermatologic recovery with thromboembolic protection. Though limited by the case-report nature of evidence, consistent temporal association and resolution with withdrawal strongly suggest a causal relationship.